Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

280 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser RA, Trenkwalder C, Ehret R, Azulay JP, Isaacson S, Felt L, Stempien MJ. Oertel W, et al. Among authors: azulay jp. Mov Disord. 2017 Dec;32(12):1701-1709. doi: 10.1002/mds.27131. Epub 2017 Aug 21. Mov Disord. 2017. PMID: 28833562 Free PMC article. Clinical Trial.
Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations.
Brittain C, McCarthy A, Irizarry MC, McDermott D, Biglan K, Höglinger GU, Lorenzl S, Del Ser T, Boxer AL; AL-108-231 Study Group; PROPSPERA investigators; 4RNTI-1authors; Tau Restoration on PSP (TAUROS) Investigators. Brittain C, et al. Parkinsonism Relat Disord. 2019 Mar;60:138-145. doi: 10.1016/j.parkreldis.2018.08.025. Epub 2018 Sep 4. Parkinsonism Relat Disord. 2019. PMID: 30201421 Free PMC article. Clinical Trial.
Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial.
Corvol JC, Durif F, Meissner WG, Azulay JP, Haddad R, Guimarães-Costa R, Mariani LL, Cormier-Dequaire F, Thalamas C, Galitzky M, Boraud T, Debilly B, Eusebio A, Houot M, Dellapina E, Chaigneau V, Salis A, Lacomblez L, Benel L, Rascol O; French NS-Park/F-CRIN Network. Corvol JC, et al. Among authors: azulay jp. Parkinsonism Relat Disord. 2019 Mar;60:51-56. doi: 10.1016/j.parkreldis.2018.10.005. Epub 2018 Oct 4. Parkinsonism Relat Disord. 2019. PMID: 30297210 Clinical Trial.
Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients.
Isaacson SH, Ballard CG, Kreitzman DL, Coate B, Norton JC, Fernandez HH, Ilic TV, Azulay JP, Ferreira JJ, Abler V, Stankovic S; 015 Study Group. Isaacson SH, et al. Among authors: azulay jp. Parkinsonism Relat Disord. 2021 Jun;87:25-31. doi: 10.1016/j.parkreldis.2021.04.012. Epub 2021 Apr 28. Parkinsonism Relat Disord. 2021. PMID: 33933853 Free article. Clinical Trial.
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Front Neurol. 2021 Oct 1;12:705407. doi: 10.3389/fneur.2021.705407. eCollection 2021. Front Neurol. 2021. PMID: 34659081 Free PMC article.
Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies.
Rascol O, Tönges L, deVries T, Jaros M, Quartel A, Jacobs D; ALLAY-LID I and ALLAY-LID II study groups. Rascol O, et al. Parkinsonism Relat Disord. 2022 Mar;96:65-73. doi: 10.1016/j.parkreldis.2022.01.022. Epub 2022 Feb 8. Parkinsonism Relat Disord. 2022. PMID: 35227940 Free article. Clinical Trial.
Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program.
Odin P, Ray Chaudhuri K, Slevin JT, Volkmann J, Dietrichs E, Martinez-Martin P, Krauss JK, Henriksen T, Katzenschlager R, Antonini A, Rascol O, Poewe W; National Steering Committees. Odin P, et al. Parkinsonism Relat Disord. 2015 Oct;21(10):1133-44. doi: 10.1016/j.parkreldis.2015.07.020. Epub 2015 Jul 23. Parkinsonism Relat Disord. 2015. PMID: 26233582 Free article. Review.
Suggestive association between OPRM1 and impulse control disorders in Parkinson's disease.
Cormier-Dequaire F, Bekadar S, Anheim M, Lebbah S, Pelissolo A, Krack P, Lacomblez L, Lhommée E, Castrioto A, Azulay JP, Defebvre L, Kreisler A, Durif F, Marques-Raquel A, Brefel-Courbon C, Grabli D, Roze E, Llorca PM, Ory-Magne F, Benatru I, Ansquer S, Maltête D, Tir M, Krystkowiak P, Tranchant C, Lagha-Boukbiza O, Lebrun-Vignes B, Mangone G, Vidailhet M, Charbonnier-Beaupel F, Rascol O, Lesage S, Brice A, Tezenas du Montcel S, Corvol JC; BADGE-PD study group. Cormier-Dequaire F, et al. Among authors: azulay jp. Mov Disord. 2018 Dec;33(12):1878-1886. doi: 10.1002/mds.27519. Epub 2018 Nov 16. Mov Disord. 2018. PMID: 30444952
280 results